Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent Checkpoint Inhibitor Therapy in Advanced Urothelial Carcinoma
NCT04322643Phase 2Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Mar 2020
- Primary completion
- Aug 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, atezolizumab, durvalumab, nivolumab, avelumab in urothelial carcinoma (UC), sponsored by Case Comprehensive Cancer Center. Started Mar 2020; status: terminated.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04322643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322643.